CTIM-07. PHASE IIB RANDOMIZED, BLINDED, CONTROLLED TRIAL EVALUATING NEOADJUVANT PD-1 BLOCKADE COMBINED WITH A2B5+ GLIOMA STEM-LIKE CELL LYSATE-LOADED DCV IN RECURRENT GLIOBLASTOMA (IDH1/2 -)- TRAIL IN PROGRESS
Yu Yao(Qinghai University), Liangfu Zhou(Fudan University), Chunxia Ji(Shanghai Public Health Clinical Center), Bingyi Zhou(Shanghai CASB Biotechnology (China)), Xiaoming Huang(Nanchong Central Hospital), Lang Hu(Sun Yat-sen University), Yuan Wang(Fudan University), Di Chen(Fudan University), Nan Zhou(Chinese Academy of Sciences), Lingchao Chen(Allen Institute for Brain Science), Chenwei Li
Cited by 0
Related Papers
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
Temozolomide-associated hypermutation in gliomas
|Neuro-Oncology|2018|227
Adult IDH wild-type lower-grade gliomas should be further stratified
|Neuro-Oncology|2017|222